Antti Vuolanto, CEO of Herantis Pharma, discusses the significant unmet need in Parkinson’s disease and outlines Phase II plans for the company’s lead asset HER-096.

Herantis’s ‘Elegant’ Approach In Parkinson’s

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

Share Herantis’s ‘Elegant’ Approach In Parkinson’s

Sign up to save your podcasts

Herantis’s ‘Elegant’ Approach In Parkinson’s

Herantis’s ‘Elegant’ Approach In Parkinson’s

More shows like Citeline Podcasts

Marketplace Tech

WSJ Your Money Briefing

WSJ What’s News

Bloomberg Intelligence

HBR IdeaCast

How to Be Awesome at Your Job

GZERO World with Ian Bremmer

The Readout Loud

Thoughts on the Market

The Journal.

The Next Big Idea

BioCentury This Week

Coaching Real Leaders

Biotech Hangout

HBR On Leadership